Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2022
Sep 12, 2022
8:30 AM EDT
The inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia , Senior Member of the Immunology Department at Moffitt Cancer Center, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 14 th Biennial Ovarian Cancer Research Symposium.
Aug 31, 2022
8:30 AM EDT
It will present a company update at the H.C. Wainwright 24 th Annual Global Investment Conference being held September 12-14, 2022 (Hybrid Conference).
Aug 15, 2022
8:30 AM EDT
That, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the first patient in the clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
Jul 21, 2022
8:30 AM EDT
The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel breast cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic.
Jun 21, 2022
8:30 AM EDT
The publication of a peer-reviewed journal article in Clinical and Experimental Vaccine Research. The article is titled, "Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas." This paper authored by Suparna Mazumder , Ph.D.,…
May 05, 2022
8:30 AM EDT
It will present a company update at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 (Hybrid Conference).
Apr 28, 2022
8:30 AM EDT
A presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022 .
Apr 06, 2022
8:30 AM EDT
The inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at The 4 th International Workshop on CAR-T (iwCAR-T) 2022 on Friday, April 29, 2022 . Dr.
Mar 30, 2022
12:45 PM EDT
The initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell (CER-T) since the target of the engineered T-cells is an endocrine receptor.
Mar 17, 2022
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the Company will present at the 2022 Virtual Growth Conference, hosted by M-Vest, a division of Maxim Group LLC, on March 28 th – 30 th from 9:00 am – 5:00 pm…
Jan 25, 2022
8:30 AM EST
The Japanese Patent Office has issued a Decision to Grant of a patent to Cleveland Clinic titled, "Ovarian Cancer Vaccines." The technology was invented by Drs. Vincent K. Tuohy , Suparna Mazumder and Justin M. Johnson at Cleveland Clinic. Anixa is the worldwide licensee for the vaccine technology.
Jan 24, 2022
8:30 AM EST
The company and its partner, MolGenie GmbH, have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting M pro , the main protease of the SARS-CoV-2 virus. Nirmatrelvir is the main component of Pfizer's PAXLOVID ™ , which was recently authorized to treat COVID-19.
2021
Dec 16, 2021
8:30 AM EST
The Company is participating in the LifeSci Partners 11 th Annual Corporate Access Event, which will be held virtually from January 5-7 , 2022, and the H.C. Wainwright BioConnect Conference, which will be held January 10-13, 2022 .
Dec 07, 2021
8:30 AM EST
The results of a genomic variant analysis done with its partner, MolGenie, GmbH, on potential compounds to treat COVID-19. The data indicate that the compounds in development should be effective against the Omicron variant of SARS-CoV-2, in addition to the previously identified Delta variant of the virus.
Oct 26, 2021
8:35 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that, in conjunction with its partner, Cleveland Clinic, it has commenced dosing of patients for a novel study of its vaccine that is being investigated…
Oct 06, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the China National Intellectual Property Administration (CNIPA) has issued a Notification of Grant of Patent Right on Anixa's novel Chimeric Antigen…
Oct 01, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S.
Sep 14, 2021
8:31 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the inventor of its ovarian cancer CAR-T technology, Dr.
Sep 08, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at the virtual H.C.
Sep 07, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today the appointment of Pamela D. Garzone , Ph.D., as Chief Development Officer. Dr.